Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Spontaneous Hyperventilation in Severe Traumatic Brain Injury Patients: The Efficiency and Safety of Remifentanil Infusion and Its Impact on Cerebral Blood Flow

NCT04974060 is registered in ClinicalTrials.gov with Capital Medical University as lead sponsor.

NCT NCT04974060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04974060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Spontaneous Hyperventilation in Severe Traumatic Brain Injury Patients: The Efficiency and Safety of Remifentanil Infusion and Its Impact on Cerebral Blood Flow
Lead sponsor
Capital Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
June 1, 2021
Completion date
March 31, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperventilation, traumatic brain injury